

## UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/064,627	10/064,627 07/31/2002		Mohsen Shahinpoor	GED-1	8855	
27232	7590	07/05/2005		EXAMINER		
MOHSEN				WEDDINGTO	WEDDINGTON, KEVIN E	
909 VIRGII ALBERQU		NM 87108		ART UNIT	PAPER NUMBER	
				1614		

DATE MAILED: 07/05/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

		Annlianti	on No	Applicant(c)	·				
	,		Application No.		Applicant(s)				
Office Action Summary		10/064,6	27	SHAHINPOOR ET AL.					
	Office Action Summary	Examine	r '	Art Unit					
			Weddington	1614					
<i> 1</i> Period for R	the MAILING DATE of this commu Reply	nication appears on the	e cover sheet wit	th the correspondence ac	ldress				
THE MA - Extensior after SIX - If the peri - If NO per - Failure to Any reply	TENED STATUTORY PERIOD F ILING DATE OF THIS COMMUN is of time may be available under the provision: (6) MONTHS from the mailing date of this com od for reply specified above is less than thirty ( iod for reply is specified above, the maximum s reply within the set or extended period for repl received by the Office later than three months atent term adjustment. See 37 CFR 1.704(b).	IICATION. s of 37 CFR 1.136(a). In no ev munication. 30) days, a reply within the stat tatutory period will apply and w y will, by statute, cause the app	vent, however, may a re tutory minimum of thirty vill expire SIX (6) MON plication to become AB	pply be timely filed  (30) days will be considered time  THS from the mailing date of this of  ANDONED (35 U.S.C. § 133).	ly. ommunication.				
Status									
1)⊠ Re	esponsive to communication(s) fil	ed on <u>18 April 2005</u> .							
2a) ☐ Th	is action is FINAL.	2b)⊠ This action is r	non-final.						
-	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.								
Disposition	of Claims								
4a) 5)□ Cl: 6)⊠ Cl: 7)□ Cl:	aim(s) 1-23 is/are pending in the of the above claim(s) 3-23 is/are aim(s) is/are allowed.  aim(s) 1 and 2 is/are rejected.  aim(s) is/are objected to.  aim(s) are subject to restricts	e withdrawn from con			· .				
Application	Papers			·					
9)∐ The	e specification is objected to by the	ne Examiner.							
	e drawing(s) filed on is/are								
<u>-</u>	plicant may not request that any obje				<del></del>				
	placement drawing sheet(s) includin e oath or declaration is objected t	-							
Priority und	ler 35 U.S.C. § 119				•				
12) Acl a) 4. 1.[ 2.[ 3.[	knowledgment is made of a claim  All b) Some * c) None of:  Certified copies of the priority  Copies of the certified copies application from the Internation	y documents have been y documents have been to find the priority documental Bureau (PCT Ru	en received. en received in A ents have been lle 17.2(a)).	pplication No received in this National	: Stage				
Attachment(s)									
2) Notice of 3) Informati	References Cited (PTO-892) Draftsperson's Patent Drawing Review ( on Disclosure Statement(s) (PTO-1449 o o(s)/Mail Date		Paper No(s	ummary (PTO-413) s)/Mail Date nformal Patent Application (PT 	O-152)				

U.S. Patent and Trademark Office PTOL-326 (Rev. 1-04)

Art Unit: 1614

Claims 1-23 are presented for examination.

Applicants' amendment filed April 18, 2005 has been received and entered.

Claims 3-13, 17 and 18 again will not be examined with the remaining claims since the claims were referred to non-elected species.

Claims 4-9 and 11-23 were withdrawn as stated in the amendment filed April 18, 2005.

Claims 1 and 2 are pending.

## Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1 and 2 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

In this regard, the application disclosure and claims have been compared per factors indicated in the decision <u>In re Wands</u>, 8 USPQ2d 1400 (Fed. Cir., 1988) as to undue experimentation.

The factors include:

Art Unit: 1614

- 1) the quantity of experimentation necessary
- 2) the amount of direction or guidance provided
- 3) the presence or absence of working examples
- 4) the nature of the invention
- 5) the state of the art
- 6) the relative skill of those in the art
- 7) the predictability of the art and
- 8) the breadth of the claims

The instant specification fails to provide guidance that would allow the skilled artisan background sufficient to practice that instant invention without resorting to undue experimentation in view of further discussion below.

The nature of the invention, state of the prior art, relative skill of those in the art and the predictability of the art

The claimed invention relates to a method for lowering ocular hypertension, comprising administering to a patient in need thereof, a topical ophthalmic eye drop for ointment containing Nitric Oxide (NO) releasing agent, Pyrrimidine and cGMP-PDE5 inhibitor, Sildenafil Citrate.

The relative skill of those in the art is generally that of a Ph.D. or M.D.

The present invention is unpredictable unless experimentation is shown for the combination of the pyrimidine and sildenafil citrate

Art Unit: 1614

The amount of direction or guidance provided and the presence or absence of working examples

No working examples showing the instant combination of pyrimidine and sildenafil citrate will lower ocular hypertension.

The quantity of experimentation necessary

Applicants have failed to provide guidance as to how the combination of pyrimidine and sildenafil citrate is effective to lower ocular hypertension. The level of experimentation needed to determine the combination of pyrimidine and sildenafil citrate would be able to lower ocular hypertension is undue. Therefore, undue experimentation would be required to practice the invention as it is claimed in its current scope.

Claims 1 and 2 are not allowed.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1 and 2 are again rejected under 35 U.S.C. 103(a) as being unpatentable over Nathanson (Journal of Pharmacology and Experimental

Art Unit: 1614

Therapeutics (1992), 260(3), 956-965) in view of Laties (EP 1,074,258 A2), all of record, for reasons of record as set forth in the Office action dated October 26, 2004 at pages 4 and 5 as applied to claims 1, 2, 19 and 20.

Applicants' remarks regarding the prior art does not teach the combination of pyrimidine (Minoxidil) and sildenafil citrate are not persuasive since the instant rejection is based upon the well established principle of patent law that no invention resides in combining 2 or more ingredients of known character where the results obtained are no more than the additive effects of the individual ingredients. It has not been demonstrated on the record by means of experimental data commensurate in scope with the claimed subject matter that applicants' combination produces any unobvious or unexpected results. The mere arguments of applicants are insufficient to overcome the strong <u>prima facie</u> case of obviousness without the experimental data.

The rejection made under 35 USC 103 is adhered to.

Claims 1 and 2 are not allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kevin E. Weddington whose telephone number is (571)272-0587. The examiner can normally be reached on 11:00 am-7:30 pm.

Application/Control Number: 10/064,627 Page 6

Art Unit: 1614

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low can be reached on (571)272-0951. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Kevin E. Weddington Primary Examiner Art Unit 1614

K. Weddington June 30, 2005